MEF2D and acute lymphoblastic leukemia: With the progressive decrease in the cost of RNA-seq and the increase in the availability of bioinformatics analysis tools, RNA-seq may represent the best strategy to identify not only kinase fusions but also other novel ALL subtypes such as ETV6-RUXN1-like and ALL with ZNF384 and MEF2D fusions16,21.